Knight Lends a Second Hand to Bloom Burton Debt Fund
MONTREAL, QUEBEC–(Marketwired – Aug 12, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has invested $1 million in the Bloom Burton Healthcare Lending Trust II (the “Trust”) managed by Stratigis Capital Advisors Inc. as part of a minimum $5 million private placement. The Trust will use […]
Knight Reports Second Quarter 2016 Results
MONTREAL, QUEBEC–(Marketwired – Aug 11, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2016. All figures are in thousands of Canadian dollars except for share and per share amounts. Key Events in Second Quarter 2016 Announced […]
Knight Therapeutics Inc. Announces Election of Directors
MONTREAL, QUEBEC–(Marketwired – Jun 16, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”) announced today that each director nominee listed in the Management Information Circular dated May 13, 2016 was elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec. The details of the election are […]
Knight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City
MONTREAL, QUEBEC–(Marketwired – May 31, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President and CEO, is scheduled to present at the National Bank Financial Quebec Conference on Wednesday, June 1, 2016 at 2:00 pm ET at the Hotel Le Crystal in Montreal, while […]
Knight Reports First Quarter 2016 Results
MONTREAL, CANADA–(Marketwired – May 10, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2016. In thousands of Canadian dollars except for share and per share amounts. First Quarter 2016 Highlights On January 4, 2016, Knight issued […]
Knight Finds EMPAthetic Partner for Neuragen(R) in the Middle East
MONTREAL, QUEBEC–(Marketwired – Apr 25, 2016) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it has entered into an exclusive distribution agreement with EMPA Healthcare LLC (“EMPA”) to commercialize Neuragen®, a topical natural health product used to relieve the symptoms of peripheral nerve pain, in the United Arab […]
Knight Blooms at Healthcare Investor Conference in Toronto
MONTREAL, QUEBEC–(Marketwired – Apr 25, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President and CEO, and Mr. Jeffrey Kadanoff, CFO, are scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2016 at […]
Knight Receives NOD from Health Canada for ATryn(R)
MONTREAL, QUEBEC–(Marketwired – Apr 25, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today announced that it has received a Notice of Deficiency (“NOD”) for its ATryn® New Drug Submission. In its notice, Health Canada requested additional technical information on ATryn® in order to complete its assessment of the product. […]
Knight Reports Fourth Quarter and Year-Ended December 31, 2015 Results
MONTREAL, CANADA–(Marketwired – Mar 24, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year-ended December 31, 2015. 2015 Highlights Knight secured the rights to over 20 innovative pharmaceutical products, consumer health products and medical devices, in various stages […]
Knight Receives Dividend From Medison
MONTREAL, CANADA–(Marketwired – Mar 23, 2016) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today receipt of a NIS 7.1 million [$2.4 million] dividend from Medison Biotech (1995) Ltd. (“Medison”). Knight owns 28.3% of Medison, Israels 4th largest specialty pharma company ranked by revenue. “Six months into our strategic collaboration […]
